8-K: Launch One Acquisition Corp. Announces Definitive Business Combination with Minovia Therapeutics, Paving Way for Nasdaq Listing

Launch One Acquisition Corp. has entered into a definitive Business Combination Agreement with Minovia Therapeutics Ltd., an Israeli mitochondrial therapy company, which will result in Minovia becoming a publicly traded company on Nasdaq under a new parent entity, Mito US One Ltd.

Summary

• Launch One Acquisition Corp. (SPAC) has signed a Business Combination Agreement (BCA) with Minovia Therapeutics Ltd. (Minovia) and Mito US One Ltd. (Pubco), an Israeli company, to effect a merger.
• The transaction involves two mergers: Company Merger Sub merging into Minovia, and SPAC Merger Sub merging into SPAC, with both Minovia and SPAC becoming wholly-owned subsidiaries of Pubco.
• Pubco will become a publicly traded company with its ordinary shares listed on Nasdaq, subject to Nasdaq approval.
• The total consideration for Minovia's security holders at closing will be $180 million, plus net cash proceeds from financing activities between signing and closing, payable in Pubco ordinary shares valued at the SPAC's redemption price.
• Minovia security holders are eligible for an additional $57.5 million in Pubco ordinary shares as an earnout, contingent on Pubco's share price reaching $11.50 for five consecutive trading days within five years post-closing, or Minovia initiating a Phase 3 clinical trial for its Pearson syndrome program or other pharmaceutical products.
• The transaction requires a minimum cash condition of $23 million for SPAC at closing, including funds from the trust account after redemptions and proceeds from transaction financing, after deducting SPAC's unpaid expenses.
• Minovia is required to secure at least $5 million in bridge financing within 30 days of the BCA at a pre-money equity valuation of $120 million.
• Additionally, SPAC, Minovia, and Pubco will seek at least $18 million in additional transaction financing (excluding committed capital on demand facilities).
• Key Minovia security holders, including officers and directors, will be subject to a one-year lock-up period on their Pubco shares, with early release conditions if the share price exceeds $12.00 or a change of control occurs.
• The post-closing Pubco board of directors will consist of eight members: five designated by Minovia, one by the Sponsor, and two by Alex Greystoke and Jon Bakhshi (HSC Principals), provided certain conditions are met.
• The CEO and CFO of Pubco post-closing will be the same individuals as Minovia's prior to closing, unless otherwise consented.

Sentiment

Score: 7

Explanation: The document announces a definitive business combination, indicating a significant positive step for Minovia Therapeutics to become a publicly traded company. The deal structure includes substantial consideration and potential earnouts, suggesting confidence in future clinical and financial performance. While there are inherent risks in biotech and SPAC transactions, the agreement provides a clear path forward and outlines financing strategies.

Positives

• The definitive agreement provides a clear path for Minovia Therapeutics to become a publicly traded company on Nasdaq, offering liquidity and access to public markets.
• The transaction includes a significant earnout potential of $57.5 million for Minovia's security holders, tied to share price performance or clinical development milestones, incentivizing future growth.
• The minimum cash condition of $23 million, combined with planned bridge and additional financing, aims to ensure adequate capital for the combined entity's operations and strategic initiatives.
• The formation of a new Pubco board with a majority of independent directors aligns with good corporate governance practices for a publicly listed company.
• The commitment to a new incentive equity plan for Pubco (10% of outstanding shares post-closing) can help attract and retain key talent.

Negatives

• The earnout is contingent and not guaranteed, depending on future share price performance or clinical trial success, which carries inherent risks.
• The Minimum Cash Condition of $23 million is a critical closing condition, and failure to meet it could jeopardize the transaction unless waived.
• The requirement for Minovia to secure at least $5 million in bridge financing within 30 days of the agreement is a tight timeline and a potential point of failure if not met.
• The Sponsor's founder shares are subject to forfeiture if earnout milestones are not met, aligning their interests but also introducing a potential loss for the Sponsor.

Risks

• The inability to complete the proposed business combination due to failure to obtain shareholder consents and approvals.
• Challenges in obtaining sufficient financing to complete the proposed business combination or satisfy other closing conditions.
• Delays in obtaining, or adverse conditions contained in, necessary regulatory approvals required to complete the transactions.
• Changes to the proposed structure of the business combination that may be required by applicable laws or regulations or as a condition to regulatory approval.
• Uncertainty regarding projections, estimates, and forecasts of revenue and other financial and performance metrics, market opportunity, and the estimated implied enterprise value of Minovia.
• Minovia's ability to scale and grow its business, and the realization of expected growth and advantages.
• Minovia's ability to source and retain talent, and the cash position of Minovia following the closing.
• The ability to meet stock exchange listing standards in connection with, and following, the consummation of the proposed business combination.
• The risk that the proposed business combination disrupts current plans and operations of Minovia due to the announcement and consummation.
• The ability to recognize the anticipated benefits of the proposed business combination, which may be affected by competition and Minovia's ability to manage growth profitably, maintain key relationships, and retain management and key employees.
• Costs related to the proposed business combination.
• Changes in applicable laws, regulations, political and economic developments.
• The possibility that Minovia may be adversely affected by other economic, business, and/or competitive factors.
• Minovia's estimates of expenses and profitability.
• Failure to realize estimated shareholder redemptions, purchase price, and other adjustments.
• Potential material infringement of third-party U.S. Patents by Minovia's products or technology, which could lead to termination of the agreement if not mitigated.

Future Outlook

Pubco is expected to become a publicly traded company listed on Nasdaq following the completion of the mergers. The future performance of the combined entity, particularly Minovia's clinical development programs for Pearson syndrome and other pharmaceutical products, is critical for triggering the earnout consideration for existing Minovia security holders. The company anticipates securing additional financing to support its operations post-closing.

Management Comments

• The boards of directors of SPAC, Minovia, Pubco, and Company Merger Sub have determined that the transactions are fair, advisable, and in the best interests of their respective companies and shareholders, and have approved the agreement and transactions.
• The post-closing Pubco board will consist of eight directors, with five designated by Minovia, one by the Sponsor, and two by the HSC Principals, subject to certain conditions.
• The chief executive officer and chief financial officer of Pubco immediately after the Closing will be the same individuals as Minovia's prior to the Closing, unless otherwise consented.

Industry Context

This business combination is part of a broader trend of biotechnology and pharmaceutical companies, particularly those focused on novel therapies like mitochondrial diseases, seeking public market access through SPAC mergers. This strategy allows private companies to bypass traditional IPO processes, potentially accelerating their access to capital for costly research and development, especially for clinical trials.

Comparison to Industry Standards

• The earnout structure, tied to both share price performance ($11.50 target) and clinical milestones (Phase 3 trial initiation or BLA approval), is a common mechanism in biotech SPAC deals to align incentives between pre-merger shareholders and new public investors, reflecting the high-risk, high-reward nature of drug development.
• The lock-up period of one year for key security holders is standard for SPAC transactions, aiming to provide stability post-merger, with early release clauses often tied to share price performance (e.g., $12.00 target) to reward early success.
• The proposed board composition, with a majority of independent directors, aligns with Nasdaq's corporate governance requirements for listed companies, a standard practice for newly public entities.

Management Changes

Corporate Governance

Related Party Transactions

• Sponsor Agreement: Launch One Sponsor LLC (Sponsor) agreed to subject 1,293,750 of its Founder Shares (Sponsor Earnout Shares) to vesting, forfeiture, and transfer restrictions. These shares will vest upon an 'Earnout Release' (achievement of earnout milestones) and will be surrendered for cancellation if no Triggering Event occurs during the Earnout Period. A portion of these shares will be held in escrow if the Minimum Cash Condition is not met but waived.
• Voting Agreements: Certain Minovia security holders, representing approximately 35% of the outstanding voting securities, entered into voting agreements to vote their shares in favor of the BCA and the Transactions.
• Lock-Up Agreements: Minovia security holders who are officers, directors, or own at least 3% of the fully-diluted equity will enter into lock-up agreements, restricting the transfer of their Pubco ordinary shares (including earnout shares) for one year post-Closing, subject to early release conditions.
• HSC Letter Agreement: Alex Greystoke and Jon Bakhshi (HSC Principals) agreed to pay for the costs and expenses of Minovia's U.S. securities counsel and PCAOB auditor. They are also granted the right to designate two directors to the Post-Closing Pubco Board if they fulfill this payment obligation and the Minimum Cash Condition is satisfied.

Stakeholder Impact

• Shareholders (Launch One Acquisition Corp.): Will have their SPAC securities converted into substantially equivalent Pubco securities and will vote on the business combination. Public shareholders have the option to redeem their shares.
• Shareholders (Minovia Therapeutics Ltd.): Will receive Pubco ordinary shares as merger consideration and have a contingent right to receive additional earnout shares, providing a path to liquidity and potential upside.
• Employees (Minovia Therapeutics Ltd.): Key executives (CEO, CFO) are expected to continue in their roles with Pubco under new employment agreements. Employees holding in-the-money options will have them converted into Pubco ordinary shares.
• Sponsor (Launch One Sponsor LLC): Their founder shares are subject to performance-based vesting and potential forfeiture, aligning their interests with the long-term success of Pubco.
• Creditors: Will be notified of the merger, as required by Israeli law, ensuring transparency regarding the corporate restructuring.
• Investment Professionals: The transaction creates a new publicly traded entity in the biotechnology sector, offering a new investment opportunity.

Next Steps

• Minovia to deliver PCAOB audited annual financial statements for 2023 and 2024, and reviewed interim financial statements for the six-month period ended June 30, 2025.
• Minovia to deliver monthly, quarterly, and annual unaudited income statements and balance sheets to SPAC.
• Parties to prepare and file a registration statement on Form F-4 with the SEC, including a proxy statement for SPAC shareholders.
• Pubco to approve and adopt a new incentive equity plan with total awards equal to 10% of outstanding shares post-Closing.
• Minovia to call a shareholder meeting or obtain written consent to approve the BCA and related matters.
• Pubco board of directors to be composed of eight directors post-Closing, with specific designations from Minovia, the Sponsor, and HSC Principals.
• Minovia, with SPAC's assistance, to seek and consummate bridge financing of at least $5 million within 30 days of the BCA.
• SPAC, Minovia, and Pubco to seek additional financing agreements for at least $18 million.
• Minovia to cause its CEO and CFO, and other specified individuals, to enter into new employment agreements with Pubco, effective at Closing.
• Minovia to ensure all Locked-Up Company Security Holders sign Lock-Up Agreements.
• SPAC to perform a freedom to operate analysis (FTO Opinion) within 30 days unless waived.
• Minovia to cause SPAC Merger Sub to be formed in the Cayman Islands and execute a joinder agreement to the BCA.
• Pubco ordinary shares to be approved for listing on Nasdaq.
• Israeli tax rulings and ISA exemptions to be obtained.
• Minovia to deliver the IIA Notice to the Israel Innovation Authority immediately after the Closing.

Key Dates

Keywords

SPAC, Business Combination, Merger, Minovia Therapeutics, Mito US One Ltd., Nasdaq Listing, Earnout, Clinical Trials, Pearson Syndrome, Biologics License Application, Bridge Financing, Transaction Financing, Lock-Up Agreement, Corporate Governance, SEC Filing, Biotechnology, Pharmaceuticals, Mitochondrial Therapies